The HealthCare Institute of New Jersey (HINJ) is a trade association that since 1997 has served as the voice for our state’s leading research-based biopharmaceutical and medical technology companies.
HINJ strives to raise awareness and appreciation of the clinical and economic value of expanding patient access to medical innovations that improve outcomes and quality of life, and works to sustain the life sciences as New Jersey’s premier industry and a pillar of the state’s economy.
Join Us for HERHealth 2026: What Women (And Men!) Need to Know
Friday, October 16, 2026 | 8 am to 11:30 am
West Hall – Middlesex College: 2600 Woodbridge Avenue, Edison, NJ 08818
Discover how New Jersey is shaping the future of medicine—one breakthrough at a time.
→ Follow NJ Innovates on LinkedIn | Browse all posts
Sign up for our NJ Innovates Updates
New Jersey proudly champions its life sciences industry and is globally recognized as the “Medicine Chest of the World” for its world-renowned cluster of life sciences companies.
For over 135 years, New Jersey has been a global leader in medical science. It offers a dynamic innovation ecosystem for researching and developing new medicines, therapies, diagnostics and technologies that improve the quality of patients’ lives. This includes over 3,200 life sciences companies and the largest concentration of scientists and engineers per square mile in the U.S.
Governor Mikie Sherrill keynotes HINJ’s 2026 annual ‘State of the Industry’ event, lauding New Jersey’s life sciences and our state’s innovation ecosystem for saving lives around the world while driving New Jersey’s workforce and economy.
We diligently monitor a number of policy debates — both in Washington, DC and Trenton.
Trenton, September 18, 2026 ― Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey (HINJ – www.hinj.org), released the following statement concerning today’s White House
September 1, 2026 ― HealthCare Institute of New Jersey (HINJ) was featured in a recent NJBIZ article examining the White House’s newly announced voluntary prescription drug pricing agreements and their
Trenton, August 31, 2026 ― Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey (HINJ – www.hinj.org), released the following statement concerning today’s White House
